DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

About DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Shell Companies
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DMPI
  • CUSIP: N/A
  • Web: www.delmarpharma.com
Average Prices:
  • 50 Day Moving Avg: $2.05
  • 200 Day Moving Avg: $3.23
  • 52 Week Range: $1.66 - $8.01
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.44
  • P/E Growth: 0.00
Profitability:
  • Return on Assets: -167.25%
Debt:
  • Current Ratio: 2.08%
  • Quick Ratio: 2.08%
Misc:
  • Average Volume: 125,256 shs.
  • Beta: 0.88
 
Frequently Asked Questions for DelMar Pharmaceuticals (NASDAQ:DMPI)

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split before market open on Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) released its quarterly earnings data on Thursday, May, 18th. The company reported ($0.18) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.18). View DelMar Pharmaceuticals' Earnings History.

When will DelMar Pharmaceuticals make its next earnings announcement?

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 31st 2017. View Earnings Estimates for DelMar Pharmaceuticals.

Where is DelMar Pharmaceuticals' stock going? Where will DelMar Pharmaceuticals' stock price be in 2017?

3 analysts have issued 12-month target prices for DelMar Pharmaceuticals' shares. Their predictions range from $11.00 to $16.00. On average, they expect DelMar Pharmaceuticals' stock price to reach $13.00 in the next year. View Analyst Ratings for DelMar Pharmaceuticals.

Who are some of DelMar Pharmaceuticals' key competitors?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:

  • Jeffrey A. Bacha, President, Chief Executive Officer, Director
  • Scott Praill, Chief Financial Officer
  • Dennis M. Brown Ph.D., Chief Scientific Officer, Director
  • John K. Bell, Lead Independent Director
  • Lynda Sarah Cranston, Independent Director
  • Erich Mohr Ph.D., Independent Director
  • Robert J. Toth Jr., Independent Director

Who owns DelMar Pharmaceuticals stock?

DelMar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include GARNER WILLIAM J (4.50%). Company insiders that own DelMar Pharmaceuticals stock include Jeffrey Bacha, John K Bell and Scott Praill. View Institutional Ownership Trends for DelMar Pharmaceuticals.

How do I buy DelMar Pharmaceuticals stock?

Shares of DelMar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DelMar Pharmaceuticals stock can currently be purchased for approximately $2.12.


MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for DelMar Pharmaceuticals (NASDAQ:DMPI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.00 (513.21% upside)

Analysts' Ratings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/24/2017HC WainwrightSet Price TargetBuy$12.00LowView Rating Details
6/23/2017Maxim GroupReiterated RatingBuy$11.00LowView Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00N/AView Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings History by Quarter for DelMar Pharmaceuticals (NASDAQ DMPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/31/2017($0.18)N/AView Earnings Details
5/18/2017($0.18)($0.18)ViewN/AView Earnings Details
2/10/201712/31/2016($0.22)($0.13)ViewN/AView Earnings Details
11/10/20169/30/2016($0.15)($0.23)ViewN/AView Earnings Details
5/13/2016($0.05)($0.03)ViewN/AView Earnings Details
2/16/2016Q2 16($0.03)($0.06)ViewN/AView Earnings Details
9/4/2015Q4 2015($0.09)($0.02)ViewN/AView Earnings Details
5/15/2015Q3 2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015Q2 2015($0.06)($0.03)ViewN/AView Earnings Details
11/10/2014Q1 2015($0.07)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DelMar Pharmaceuticals (NASDAQ:DMPI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.27)($0.19)($0.23)
Q3 20172($0.28)($0.16)($0.22)
Q4 20172($0.55)($0.36)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for DelMar Pharmaceuticals (NASDAQ:DMPI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership Percentage: 1.11%
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/26/2017Jeffrey BachaCEOBuy6,700$3.60$24,120.00View SEC Filing  
6/26/2017John K BellDirectorBuy4,167$3.60$15,001.20View SEC Filing  
6/6/2017Jeffrey BachaCEOBuy5,000$2.12$10,600.00View SEC Filing  
6/6/2017John K BellDirectorBuy10,000$2.12$21,200.00View SEC Filing  
6/6/2017Scott PraillCFOBuy9,500$2.10$19,950.00View SEC Filing  
5/5/2017Jeffrey BachaCEOBuy2,500$2.20$5,500.00View SEC Filing  
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.00View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for DelMar Pharmaceuticals (NASDAQ:DMPI)
Latest Headlines for DelMar Pharmaceuticals (NASDAQ:DMPI)
Source:
DateHeadline
finance.yahoo.com logoDelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
finance.yahoo.com - July 24 at 10:33 AM
benzinga.com logoExclusive: DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help Sen. John McCain
www.benzinga.com - July 22 at 12:50 AM
americanbankingnews.com logoDelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 20 at 12:27 AM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
finance.yahoo.com - July 18 at 7:31 PM
finance.yahoo.com logoDelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable
finance.yahoo.com - June 29 at 7:23 PM
americanbankingnews.com logoDelMar Pharmaceuticals, Inc. (DMPI) Director John K. Bell Acquires 4,167 Shares
www.americanbankingnews.com - June 28 at 4:44 PM
americanbankingnews.com logoDelMar Pharmaceuticals, Inc. (DMPI) CEO Buys $24,120.00 in Stock
www.americanbankingnews.com - June 28 at 4:30 PM
americanbankingnews.com logoDelMar Pharmaceuticals, Inc. (DMPI) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - June 25 at 11:40 PM
americanbankingnews.com logo Analysts Expect DelMar Pharmaceuticals, Inc. (DMPI) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - June 23 at 8:34 PM
americanbankingnews.com logoDelMar Pharmaceuticals, Inc. (DMPI) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - June 23 at 12:12 PM
finance.yahoo.com logoDelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
finance.yahoo.com - June 22 at 10:21 AM
finance.yahoo.com logoDelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference
finance.yahoo.com - June 16 at 5:32 PM
americanbankingnews.com logoDelMar Pharmaceuticals Inc (DMPI) Director Buys $21,200.00 in Stock
www.americanbankingnews.com - June 7 at 1:26 PM
americanbankingnews.com logoScott Praill Purchases 9,500 Shares of DelMar Pharmaceuticals Inc (DMPI) Stock
www.americanbankingnews.com - June 6 at 8:41 PM
americanbankingnews.com logoJeffrey Bacha Acquires 5,000 Shares of DelMar Pharmaceuticals Inc (DMPI) Stock
www.americanbankingnews.com - June 6 at 8:40 PM
americanbankingnews.com logoDelMar Pharmaceuticals Inc (DMPI) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 30 at 6:58 PM
americanbankingnews.com logoDelMar Pharmaceuticals Inc (DMPI) Given a $11.00 Price Target at Maxim Group
www.americanbankingnews.com - May 25 at 7:26 PM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results
finance.yahoo.com - May 19 at 8:15 AM
americanbankingnews.com logoDelMar Pharmaceuticals Inc (DMPI) Announces Earnings Results, Meets Estimates
www.americanbankingnews.com - May 19 at 7:46 AM
reuters.com logoBRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083
www.reuters.com - May 12 at 10:20 PM
finance.yahoo.com logoDelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)
finance.yahoo.com - May 8 at 9:25 AM
finance.yahoo.com logoDelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma ("GBM") at ASCO Annual Meeting
finance.yahoo.com - April 27 at 8:59 AM
finance.yahoo.com logoDelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme
finance.yahoo.com - April 25 at 11:49 AM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants
finance.yahoo.com - April 21 at 12:15 PM
americanbankingnews.com logoMaxim Group Analysts Give DelMar Pharmaceuticals Inc (DMPI) a $11.00 Price Target
www.americanbankingnews.com - April 13 at 8:08 PM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants
finance.yahoo.com - April 13 at 11:39 AM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
finance.yahoo.com - April 12 at 4:48 PM
streetinsider.com logoDelmar Pharma (DMPI) Provides VAL-083 Updates from AACR Meeting - StreetInsider.com
www.streetinsider.com - April 7 at 4:46 PM
finance.yahoo.com logoDelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 7 at 9:27 AM
americanbankingnews.com logoDelMar Pharmaceuticals Inc (DMPI) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - April 5 at 4:09 PM
streetinsider.com logoDelmar Pharma (DMPI) Announces Abstract Presentations for AACR - StreetInsider.com
www.streetinsider.com - March 29 at 8:21 PM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017
finance.yahoo.com - March 28 at 12:09 PM
finance.yahoo.com logoDelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD
finance.yahoo.com - March 2 at 10:14 AM
finance.yahoo.com logoDMPI: Three New Clinical Trials of VAL-083 To be Initiated in 2017
finance.yahoo.com - February 28 at 4:58 PM
finance.yahoo.com logoDELMAR PHARMACEUTICALS, INC. Financials
finance.yahoo.com - February 16 at 2:46 PM
streetinsider.com logoDelmar Pharma (DMPI) Doses First Patient in Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM
www.streetinsider.com - February 13 at 5:29 PM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results
finance.yahoo.com - February 13 at 5:28 PM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
finance.yahoo.com - February 13 at 5:28 PM
finance.yahoo.com logoDelMar Pharmaceuticals, Inc. - "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson"
finance.yahoo.com - January 30 at 10:43 AM
streetinsider.com logoDelmar Pharma (DMPI), MD Anderson Initiate New Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM
www.streetinsider.com - January 26 at 3:58 AM
us.rd.yahoo.com logoDelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
us.rd.yahoo.com - January 25 at 5:57 PM
finance.yahoo.com logoDelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083
finance.yahoo.com - January 9 at 4:37 PM
finance.yahoo.com logoDelMar Pharmaceuticals, Inc. - "21st Century Cures Act - A Holiday Gift for New Research in the Fight Against Cancer and Other Serious Diseases"
finance.yahoo.com - December 20 at 9:50 AM
us.rd.yahoo.com logoDelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083
us.rd.yahoo.com - December 14 at 5:48 PM
us.rd.yahoo.com logo8:12 am DelMar Pharma receives a Notice of Allowance from the USPTO for patent entitled, 'Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol'
us.rd.yahoo.com - December 14 at 5:48 PM
finance.yahoo.com logoACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors
finance.yahoo.com - December 13 at 10:27 PM
us.rd.yahoo.com logoDMPI: Three New Clinical Trials with VAL-083 will be Initiated
us.rd.yahoo.com - November 29 at 5:42 PM
finance.yahoo.com logoDelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting
finance.yahoo.com - November 24 at 8:56 AM
finance.yahoo.com logoDelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
finance.yahoo.com - May 25 at 8:00 AM
finance.yahoo.com logoDelMar Pharmaceuticals, Inc. - "Reverse Stock Splits & Uplisting"
finance.yahoo.com - May 19 at 10:32 AM

Social

Chart

DelMar Pharmaceuticals (DMPI) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff